Reshaping the HIV treatment and prevention landscape
Pipeline with multiple potential first- and/or best-in-class assets
Total number of candidates
9 assets
RSV/Pertussis combo
Gonorrhea
COVID 2nd Gen (CureVac)
Klebsiella pneumoniae
CMV
Th HSV
Varicella new strain (US)
HPV NG
mRNA seasonal Flu (CureVac)
FIC/
BIC
BIC
AS
BIC
AS BIC
4 assets
AS
FIC/
BIC
MenABCWY (2nd Gen)
C. difficile*
AS
SAM (rabies model)*
BIC
SAM (COVID-19 model)*
Phase 1
Next wave of entrants ('21/'22) *
**
FIC First-in-class BIC Best-in-class AS Adjuvant system
mRNA
AS
45
10 assets
Menveo liquid^^
Shingrix immuno-compromised* As
FIC
Bexsero in infants (US)
BIC
MMR (US)
FIC/
BIC
Rotarix liquid (US)
AS
BIC
MenABCWY 1st gen.
FIC/
BIC
45
FIC/
BIC
RSV maternal*
BIC
6 assets
RSV paediatric
Therapeutic HBV*
BIC
Malaria* (fractional dose)
AS
BIC
Shigella*
COVID-19 (SK Bioscience)*^
AS
S. aureus*
Phase 2
FIC
RSV older adults*
AS
FIC/
BIC
COVID-19 (Sanofi)*^
AS
AS
FIC/
BIC
COVID-19 (Medicago)*^
AS
Phase 3 / Registrational
gsk
Potential for:
5
new launches
by 2026
5
POCS
by 2023
5
FTIH starts
in 2021
*In-license or other alliance relationship with third party
**New wave of entrants exclude Global Health targets;
^GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations; ^^Ph2 registrational trial
Pipeline information updated June 2021
5 new launches by 2026: RSV OA, RSV maternal, Men ABCWY 1st gen, COVID-19 NG, MMR US
5 PoC by 2023: Men ABCWY-7B 2nd gen, mRNA improved flu, RSV ped, Th HBV, Staph aureus
5 FTIH starts in 2021: COVID-19 NG, Men ABCWY-7B 2nd gen, Klebsiella pneumonia, CMV, Varicella NS
62View entire presentation